In the latest trading session,, 0.61 million NRX Pharmaceuticals Inc (NASDAQ:NRXP) shares changed hands as the company’s beta touched 1.58. With the company’s most recent per share price at $2.89 changing hands around $0.11 or 3.90% at last look, the market valuation stands at $49.93M. NRXP’s current price is a discount, trading about -107.96% off its 52-week high of $6.01. The share price had its 52-week low at $1.10, which suggests the last value was 61.94% up since then.
Analysts gave the NRX Pharmaceuticals Inc (NRXP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NRXP as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. NRX Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.31.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) trade information
Instantly NRXP is in green as seen in intraday trades today. With action 27.24%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 31.29%, with the 5-day performance at 27.24% in the green. However, in the 30-day time frame, NRX Pharmaceuticals Inc (NASDAQ:NRXP) is 51.22% up.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need a downside of -44.5% from its recent market value. According to analyst projections, NRXP’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a 30.8% surge from its current level, while the stock would need to tank 30.8% for it to hit the projected low.
1 analysts are of the opinion that NRX Pharmaceuticals Inc’s revenue for the current quarter will be 13.5M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for NRX Pharmaceuticals Inc earnings to increase by 95.13%.
NRXP Dividends
NRX Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.
Among Mutual Funds, the top two as of Apr 30, 2025 were AdvisorShares Trust-AdvisorShares Psychedelics ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 297.8 shares estimated at $0.86 million under it, the former controlled 1.72% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.12% of the shares, roughly 193.42 shares worth around $0.56 million.
